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Background: Lack of viral load monitoring of ART is known to be associated with slower switch from a failing regi-
men and thereby higher prevalence of MDR HIV-1. Many countries have continued to use thymidine analogue
drugs despite recommendations to use tenofovir in combination with a cytosine analogue and NNRTI as first-
line ART. The effect of accumulated thymidine analogue mutations (TAMs) on phenotypic resistance over time
has been poorly characterized in the African setting.
Patients and methods: A retrospective analysis of individuals with ongoing viral failure between weeks 48 and
96 in the NORA (Nevirapine OR Abacavir) study was conducted. We analysed 36 genotype pairs from weeks
48 and 96 of first-line ART (14 treated with zidovudine/lamivudine/nevirapine and 22 treated with zidovudine/la-
mivudine/abacavir). Phenotypic drug resistance was assessed using the Antivirogram assay (v. 2.5.01, Janssen
Diagnostics).
Results: At 96 weeks, extensive TAMs (3 mutations) were present in 50% and 73% of nevirapine- and abacavir-
treated patients, respectively. The mean (SE) number of TAMs accumulating between week 48 and week 96 was
1.50 (0.37) in nevirapine-treated participants and 1.82 (0.26) in abacavir-treated participants. Overall, zidovudine
susceptibility of viruses was reduced between week 48 [geometric mean fold change (FC) 1.3] and week 96
(3.4, P"0.01). There was a small reduction in tenofovir susceptibility (FC 0.7 and 1.0, respectively, P"0.18).
Conclusions: Ongoing viral failure with zidovudine-containing first-line ART is associated with rapidly increasing
drug resistance that could be mitigated with effective viral load monitoring.
Introduction
Combination ART (cART) has led to declining mortality and HIV-1
incidence in high-prevalence settings.1,2 WHO recommends teno-
fovir/lamivudine/emtricitabine as the NRTI backbone of cART.3
Although countries have scaled up use of tenofovir, thymidine
analogues such as stavudine or zidovudine are still in use.
Virological failure occurs in 15%–35% of patients treated with thy-
midine analogue-containing first-line cART within the first year,
with the majority harbouring resistance to NNRTI and lamivudine
in areas without access to viral load monitoring.4,5 As tenofovir be-
comes available, increasing numbers of individuals are substituting
thymidine analogues for tenofovir without documented viral sup-
pression at switch, carrying risk for acquisition of drug resistance.4,5
There is also evidence pointing to prior undisclosed thymidine
analogue-containing ART in patients presenting for first-line
tenofovir-based ART in sub-Saharan Africa.6,7 Unsurprisingly,
therefore, thymidine analogue mutations (TAMs) have been re-
ported in patients following viral failure of tenofovir-containing
first-line regimens,8 contributing to multidrug resistance in these
individuals.9 As limitation of emergence and transmission of MDR
HIV is a priority, understanding the accumulation and phenotypic
impact of TAMs remains important.
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Despite a large body of data on HIV-1 resistance mutations in
cross-sectional adult treatment studies from Africa,10 there are
few longitudinal data on accumulation of drug resistance during
prolonged viral failure of first-line cART regimens, and even less in-
formation on the phenotypic impact of such accumulated muta-
tions. We sought to address these gaps in current knowledge
through a retrospective analysis of individuals with ongoing viral
failure between 48 and 96 weeks in the NORA (Nevirapine OR
Abacavir) sub-study of the DART (Development of AntiRetroviral
Therapy in Africa) trial.
Patients and methods
DART-NORA enrolled 600 previously untreated and asymptomatic
Ugandan patients with CD4 counts of,200 cells/mm3, who were randomly
assigned to co-formulated zidovudine/lamivudine and either abacavir and
nevirapine placebo (n"300), or abacavir placebo and nevirapine (n"300).
After 24 weeks, participants continued to receive the study drugs open-
label and were followed up as part of DART. Of those randomized, 32 died
before week 96, and 21 were lost to follow-up. A further 107 participants
with CD4 counts300 cells/mm3 at weeks 48 or 72 after ART initiation
were randomized to structured treatment interruption (STI) with up to four
repeated cycles of 12 weeks on/off therapy and are excluded. In addition,
7 (4 abacavir, 3 nevirapine) participants had switched to lopinavir-based
second-line ART by week 96, leaving 433 participants (236 abacavir,
197 nevirapine), for whom 96.7% of week 48 and week 96 HIV-1 RNA
measurements were available.
Viral loads were measured using Roche Amplicor 1.5. Genotypic resist-
ance testing was by standard population sequencing of pol, with identifica-
tion of resistance mutations according to the latest IAS-USA list,11 as
described previously.12 Phenotypic drug resistance was assessed using the
Antivirogram assay (v. 2.5.01, Janssen Diagnostics) using a full-length re-
combinant HIV vector containing patient-derived protease (PR)–reverse
transcriptase (RT) sequences up to codon 400 of RT.13 Nested RT–PCR was
used to amplify a 2.2 kb fragment and the resulting PR–RT-coding se-
quences were then transfected into CD4! T lymphocytes (MT4), along with
the pGEMT3deltaPRT plasmid. Chimeric viruses containing PR- and RT-
coding sequences derived from HIV-1 RNA in plasma were generated
through homologous recombination in the MT4 cells, and susceptibilities of
chimeric viruses to RT inhibitors were determined by an MT4 cell 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based cell viability
assay.14 Statistical methods included Student’s t-tests and linear regression
as appropriate. All P values were two-sided. All analyses were performed
using STATA v. 14.0 (StataCorp LP, College Station, TX, USA).
Ethics
Ethics approval both for DART and the NORA sub-study was obtained both
in Uganda [Uganda Research Unit on AIDS (UVRI) Science and Ethics
Committee] and the UK (Imperial College).
Results
Fifty-one of 433 (12%) participants were identified as having a viral
load .1000 copies/mL at both week 48 and week 96 (Figure 1).
Genotypic and phenotypic testing was attempted at these time-
points along with a baseline (week 0) sample. Genotyping was suc-
cessful for 49 pairs of samples. Of these participants, 7 made
substitutions to their initial regimen, 4 had detectable resistance
mutations prior to starting therapy, and 2 had no major mutations
at both weeks 48 and 96, indicating non-adherence; all were
excluded from further analyses, leaving 36 individuals with
genotype pairs (22 abacavir, 14 nevirapine). Paired phenotypic re-
sults from both weeks 48 and 96 were only available in 16 of these
36 participants due to insufficient quantity of sample for pheno-
typing in the remainder (Figure 1). Twenty-four (67%) of the par-
ticipants with a genotype were female, with a median (IQR) age at
randomization of 37 (30–43) years. The CD4 count at randomiza-
tion was low, with a median (IQR) value of 44 (17–103) cells/mm3.
The relationship between an individual’s viral load at weeks
48 and 96 is shown in Figure 2. In participants with paired geno-
typic data randomized to the nevirapine group (n"14), mean (SD)
viral load was 4.67 (0.49) log10 copies/mL at week 48 and
4.52 (0.55) log10 copies/mL at week 96 [mean decrease of 0.15
log10 copies/mL (95% CI #0.06–0.36)]. In those randomized to
abacavir (n"22), the mean viral load was 4.13 (0.72) log10 copies/
mL at week 48 and 4.50 (0.66) log10 copies/mL at week 96 [mean
increase of 0.37 log10 copies/mL (95% CI 0.10–0.64)].
Overall, the prevalence of each TAM increased between weeks
48 and 96 in our sample of 36 patients [mean absolute increase
25% (range 19%–31%)]. TAMs at position 215 were particularly
frequent (.70% in each arm) followed by D67N (Table 1). In only
one case was there a loss of a specific TAM between timepoints
(D67N in the nevirapine arm). At 48 weeks,3 TAMs were present
in 14% and 23% of nevirapine- and abacavir-treated patients, re-
spectively, and at 96 weeks the proportions were 50% and 73%,
respectively. The mean (SE) number of TAMs accumulating be-
tween weeks 48 and 96 was 1.50 (0.37) in nevirapine-treated pa-
tients and 1.82 (0.26) in abacavir-treated patients. This rate of
accumulation was not related to the absolute number of TAMs at
week 48 (P" 0.38), although numbers in each group were small.
Combining both treatment arms, the zidovudine susceptibility
of viruses was reduced between week 48 [geometric mean fold
change (FC) 1.3] and week 96 (geometric mean FC 3.4, P"0.01)
(Figure 3a). Similarly, there was a small, non-significant reduction
in tenofovir disoproxil fumarate susceptibility over time (FC 0.7 and
1.0, respectively, P"0.18) (Figure 3b) with most patients remain-
ing fully susceptible. However, there were no observed changes in
susceptibility to abacavir (FC 1.9 and 1.9, respectively, P"0.96) be-
tween these timepoints (Figure 3c).
Lamivudine resistance (M184V) was present in all patients with
viral failure at 96 weeks except one participant on the nevirapine
arm (Table 1), and had emerged by week 48 in all but one patient
on the nevirapine arm. Other NRTI-associated mutations were pre-
sent only in participants on the abacavir arm, and had emerged by
week 48: one individual acquired the multinucleoside resistance
69 insertion, one acquired K65R and two acquired Y115F (Table S1,
available as Supplementary data at JAC Online). The abacavir-
selected mutation L74V mutation was not observed in any partici-
pant (Table S1).
The connection domain mutation N348I conferring resistance
to zidovudine15,16 was acquired in 4/14 (28.6%) of nevirapine-
treated patients and in 6/22 (27.3%) of abacavir-treated patients.
Major NNRTI mutations occurred in 12/14 participants treated
with nevirapine by week 48. In those who were already resistant
by week 48, only one participant acquired a new mutation by week
96 (V106A at week 48, K101E!G190A at week 96), and both par-
ticipants without NNRTI mutations at week 48 went on to develop
G190A by week 96.
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Discussion
NNRTI-based cART appears to be associated with rapid accumula-
tion of TAMs in those with virological failure (1.50 TAMs per year
for zidovudine/lamivudine/nevirapine-treated patients) in this re-
source-limited setting where routine viral load monitoring is not
performed. We observed that abacavir/zidovudine/lamivudine
also resulted in rapid TAM accumulation (1.82 TAMs per year), al-
though WHO guidelines do not currently recommend triple
nucleoside-based cART for first-line cART. Our estimate of TAM ac-
cumulation for NNRTI-based ART is higher than reported previ-
ously in South African adults17 (0.84 per year), and in Zambian
children18 (0.5 per year). Both those studies involved significant
stavudine use, as opposed to zidovudine. Stavudine is known to
select not only for TAM mutational pathways, but also selects for
K65R and this could partly explain the discrepancy with our data.
Randomized n=300
96 week follow-up
On first-line
n=277
13 died
10 LTFU
4 second-
line
No STI
VL measurement 
at weeks 48 & 96
n=236
37 STI
n=226
10 missing VL
n=273
ABC
n=300
n=270
19 died
11 LTFU
3 second-
line
n=197
70 STI
n=180
17 missing VL
n=267
NVP
n=17VL >1000
copies/mL at
weeks 48 & 96
n=34
n=16Genotype available n=33
n=14
Included in
genotypic analysis n=22
n=7Phenotype available n=9
1 failed 1 failed
6 major substitution
3 baseline resistance
2 non-adherence
1 major substitution
1 baseline resistance
Figure 1. Flow diagram of participants and samples genotyped and phenotyped. ABC, abacavir; NVP, nevirapine; LTFU, lost to follow-up; VL, viral load.
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Figure 2. Scatter plot depicting week 48 versus week 96 viral load by
treatment group in patients with paired genotypes (n"36). ABC, abaca-
vir; NVP, nevirapine.
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Over half of all patients with viral failure by week 48 in this
study had3 TAMs in total by week 96. Accumulated TAMs were
associated with reduced phenotypic drug susceptibility amongst a
smaller sample of patients, with zidovudine susceptibility signifi-
cantly falling between weeks 48 and 96, and a small non-
significant decrease observed for tenofovir.
We know from previous studies that boosted PI-based first-line
ART is protective against the development of NRTI mutations, in
comparison with NNRTI-based first-line therapy.19–21 This is im-
portant to bear in mind as first-line treatment strategies in sub-
Saharan Africa may need to be changed in the coming years due
to the rising prevalence of transmitted NNRTI drug resistance.22 It
will be of interest to know whether the use of integrase inhibitors
is also protective against NRTI resistance in such settings.
Limitations
This study was limited by a relatively small number of available
phenotype pairs and the conclusions are largely drawn from
genotypic information. Furthermore the data are derived from
nevirapine-treated patients and efavirenz is now the most widely
used NNRTI in resource-limited settings.23
Despite its associated toxicity, zidovudine has emerged as an
important component of cART regimens in resource-limited set-
tings; moreover, dose reduction reduces incidence of moderate to
severe anaemia.24 WHO recommends the use of zidovudine in se-
cond-line regimens following failure of first-line regimens contain-
ing tenofovir. This presents a possible problem where patients
have accumulated TAMs prior to tenofovir replacing zidovudine
during first-line cART, though two large studies have not shown a
detrimental effect of TAMs on boosted PI-based second-line
therapy.25,26
Transmission of NRTI drug resistance compromises subsequent
response to first-line therapies,27,28 and therefore limitation of
accumulated TAMs should be a public health priority as cART is
scaled up. It is also appropriate to limit multidrug resistance as this
Table 1. Prevalence of TAMs and M184V in patients with paired geno-
types (n"36) at weeks 48 and 96, by treatment arm
ABC (n" 22) NVP (n" 14)
week 48 week 96 week 48 week 96
n % n % n % n %
Mutation
184V 22 100 22 100 12 86 13 93
41L 2 9 8 36 1 7 4 29
67N 9 41 15 68 5 36 6 43
70R 9 41 14 64 2 14 4 29
210W 0 0 7 32 1 7 5 36
215F 3 14 7 32 0 0 5 36
215Y 3 14 9 41 2 14 5 36
219QE 4 18 11 50 1 7 4 29
No. of TAMs
0 9 41 3 14 8 57 3 21
1 2 9 1 5 2 14 1 7
2 6 27 2 9 2 14 3 21
3 4 18 4 18 2 14 2 14
4 1 5 12 55 0 0 5 36
ABC, abacavir; NVP, nevirapine.
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Figure 3. Drug susceptibility of patient-derived virus isolates to abacavir,
zidovudine and tenofovir disoproxil fumarate (modelled as FCs relative
to a reference isolate) by treatment group in patients with paired pheno-
types (n"16). ABC, abacavir; NVP, nevirapine; TDF, tenofovir disoproxil
fumarate; ZDV, zidovudine.
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may allow for recycling of drugs in the future as the epidemic
matures.
Effective viral load monitoring has been identified as a priority
area29 and could avoid prolonged viral failure with accumulation
of TAMs.30 In such individuals with virological failure, adherence
counselling with possible switch to second-line therapy should be
undertaken, thus avoiding ongoing first-line failure and accumula-
tion of drug resistance.8
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